Stipple Bio announced an oncology license deal with Eli Lilly and Company on Nov. 16.
The license is exclusive and applies worldwide.
Business / Health
Stipple Bio announced the agreement on Nov. 16.

Stipple Bio announced an oncology license deal with Eli Lilly and Company on Nov. 16.
The license is exclusive and applies worldwide.
Greenoaks and Sequoia Capital co-led the round. The company also reported positive preclinical results in internal oncology and immunology programs.
Revenue rose 17% to $1.458 billion, while net product revenue increased 52% to $1.292 billion.
Calytrix Bio is a privately held biotechnology company.